XBiotech, Inc. (XBIT)
2.20
0.00 (0.00%)
USD |
NASDAQ |
Sep 04, 16:00
2.20
0.00 (0.00%)
After-Hours: 20:00
XBiotech Enterprise Value : -42.46M for Sept. 4, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 04, 2026 | -42.46M |
| September 03, 2026 | -42.46M |
| September 02, 2026 | -42.76M |
| September 01, 2026 | -41.85M |
| August 31, 2026 | -39.41M |
| August 28, 2026 | -40.32M |
| August 27, 2026 | -39.41M |
| August 26, 2026 | -39.10M |
| August 25, 2026 | -39.41M |
| August 24, 2026 | -39.10M |
| August 21, 2026 | -40.02M |
| August 20, 2026 | -39.10M |
| August 19, 2026 | -39.10M |
| August 18, 2026 | -40.32M |
| August 17, 2026 | -39.10M |
| August 14, 2026 | -39.41M |
| August 13, 2026 | -38.49M |
| August 12, 2026 | -34.53M |
| August 11, 2026 | -38.49M |
| August 10, 2026 | -40.02M |
| August 07, 2026 | -40.32M |
| August 06, 2026 | -40.02M |
| August 05, 2026 | -40.63M |
| August 04, 2026 | -41.24M |
| August 03, 2026 | -41.39M |
| Date | Value |
|---|---|
| July 31, 2026 | -41.54M |
| July 30, 2026 | -41.24M |
| July 29, 2026 | -40.93M |
| July 28, 2026 | -40.32M |
| July 27, 2026 | -40.63M |
| July 24, 2026 | -40.32M |
| July 23, 2026 | -40.02M |
| July 22, 2026 | -40.32M |
| July 21, 2026 | -41.24M |
| July 20, 2026 | -40.93M |
| July 17, 2026 | -40.32M |
| July 16, 2026 | -39.71M |
| July 15, 2026 | -39.71M |
| July 14, 2026 | -39.71M |
| July 13, 2026 | -38.49M |
| July 10, 2026 | -39.71M |
| July 09, 2026 | -39.71M |
| July 08, 2026 | -37.58M |
| July 07, 2026 | -36.97M |
| July 06, 2026 | -36.05M |
| July 02, 2026 | -39.41M |
| July 01, 2026 | -39.41M |
| June 30, 2026 | -39.41M |
| June 29, 2026 | -44.42M |
| June 26, 2026 | -44.42M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.941B |
| Alnylam Pharmaceuticals, Inc. | 35.27B |
| Anika Therapeutics, Inc. | 265.34M |
| Savara, Inc. | 960.37M |
| Vericel Corp. | 1.989B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.728M |
| Total Expenses (Quarterly) | 6.728M |
| EPS Diluted (Quarterly) | -0.2207 |
| Earnings Yield | -67.30% |
| Normalized Earnings Yield | -67.29 |